Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 15/20 | 0.53 |
| ▸ | MMP1 | P03956 | 5/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | ADAM33 | Q9BZ11 | 3/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | MMP15 | P51511 | 1/20 | 0.49 |
| ▸ | MMP16 | P51512 | 1/20 | 0.49 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.49 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600735 | 1.00 | ADAM17 (0.53) | ADAM17MMP1MMP3MMP2MMP9 | |
| SCHEMBL7450520 | 1.00 | ADAM17 (0.53) | ADAM17MMP1MMP3MMP2MMP9 | |
| SCHEMBL6597457 | 0.83 | ADAM17 (0.57) | ADAM17MMP2MMP9MMP13 | |
| SCHEMBL7404184 | 0.83 | ADAM17 (0.57) | ADAM17MMP2MMP9MMP13 | |
| SCHEMBL6597422 | 0.83 | ADAM17 (0.57) | ADAM17MMP2MMP9MMP13 | |
| Trifluoroacetic Acid SCHEMBL6600731 | 0.79 | ADAM17 (0.69) | ADAM17MMP1MMP3MMP2ADAM10 | |
| Trifluoroacetic Acid SCHEMBL6597682 | 0.79 | ADAM17 (0.69) | ADAM17MMP1MMP3MMP2ADAM10 | |
| SCHEMBL6598558 | 0.78 | ADAM17 (0.53) | ADAM17MMP2MMP9MMP13 | |
| SCHEMBL6597067 | 0.77 | MMP2 (0.55) | ADAM17MMP1MMP3MMP2MMP9 | |
| SCHEMBL6596662 | 0.77 | ADAM17 (0.51) | ADAM17MMP2MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | DUAN JINGWU (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072802-A1 | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | TNF, XPNPEP1, MMP2 | ADAM17 29/4885MMP1 6/4885MMP3 12/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | ADAM17 27/4885MMP1 4/4885MMP3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.